



# Highlights in Medicinal Chemistry II

Wednesday 23 November 2016, SCI, London, UK

Organised by SCI's Fine Chemicals Group

## Synopsis

This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focused forum to promote examples of medicinal chemistry excellence.

## Attendees

This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.

## Organising Committee

- ▶ Sarah Major, Evotec
- ▶ Joanne Pinder, Vertex
- ▶ Iain Simpson, AstraZeneca
- ▶ Mihiro Sunose, Sygnature
- ▶ Nigel Swain, Heptares

## Sponsorship

If you are interested in in sponsorship opportunities, please contact [conferences@soci.org](mailto:conferences@soci.org)

## Registration

To register for the event, please visit: [www.soci.org/events](http://www.soci.org/events). Early bird rates end on **Friday 7 October 2016**.

### Early-bird rates before 7 October

SCI/RSC Members £90  
SCI/RSC Student Members £40  
Non-Members £130

### Standard rates after 7 October

SCI/RSC Members £110  
SCI/RSC Student Members £50  
Non-Members £155

For further information, visit: [www.soci.org/events](http://www.soci.org/events)

E: [conferences@soci.org](mailto:conferences@soci.org)

T: +44 (0)20 7598 1561

The CPD Standards Office

CPD PROVIDER: 41057  
2016 - 2018

[www.cpdstandards.com](http://www.cpdstandards.com)



# Wednesday 23 November 2016

Wednesday 23 November 2016, SCI, London, UK

Organised by SCI's Fine Chemicals Group

## Programme

09.00 Registration and refreshments

09.50 Opening remarks

09.55 **The realisation of activity-directed synthesis**

Prof Adam Nelson, University of Leeds

10.35 **Structure-based design of drug-like macrocycles to probe the role of MTH1 in cancer**

Dr Jason Kettle, AstraZeneca

11.15 Refreshments

11.35 **Development of novel, selective and irreversible PI3K inhibitors**

Mr Samuel Dalton, University of Strathclyde / GlaxoSmithKline

12.00 **Discovery of the first cell-active inhibitors of poly(ADP ribose) glycohydrolase (PARG) through high-throughput screening and computational approaches**

Dr Kate Smith, Cancer Research UK Manchester Institute

12.25 **Discovery of a small molecule that mitigates hearing loss in a model of Usher syndrome III**

Dr Chris Lock, Discovery from Charles River

12.50 Lunch

13.50 **Discovery of novel TACE inhibitors for topical treatment of psoriasis**

Dr Gilles Ouvry, Galderma

14.15 **Discovery of CCT251921: A potent, selective and orally bioavailable small molecule modulator of the mediator complex-associated kinases CDK8 and CDK19**

Dr Aurélie Mallinger, The Institute of Cancer Research

14.40 **Increasing solubility for free**

Dr Timothy Ritchie, TJR-Chem

15.20 Refreshments

15.40 **Extracting actionable knowledge from large scale in vitro pharmacology data**

Dr Al Dossetter, MedChemica

16.05 **Receptor kinetics vs CNS exposure: which is more important for a ghrelin inverse agonist?**

Dr William McCoull, AstraZeneca

16.30 **Chemical probes for epigenetic proteins**

Prof Paul Brennan, University of Oxford

17.10 Closing remarks

17.15 Wine reception

## Sponsors

